Screener
Supernus Pharmaceuticals SUPN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 17) | ||
| Stockholders' equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 58,039,721 and 57,457,462 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 58 | 57 |
| Additional paid-in capital | 561,419 | 543,825 |
| Accumulated other comprehensive loss, net of tax | (255) | (44) |
| Retained earnings | 515,583 | 517,876 |
| Total stockholders' equity | 1,076,805 | 1,061,714 |
| Total liabilities and stockholders' equity | $1,500,725 | $1,452,648 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total equity?
- Supernus Pharmaceuticals (SUPN) reported total equity of $1.08B in Q1 2026.
- How has Supernus Pharmaceuticals's total equity changed year-over-year?
- Supernus Pharmaceuticals's total equity increased by 4.5% year-over-year, from $1.03B to $1.08B.
- What is the long-term trend for Supernus Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total equity has grown at a 7.3% compound annual growth rate (CAGR), from $744.86M to $1.06B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Supernus Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude